Inviting patients to participate in clinical trials exploring new combinations with anti-FGFR2b (fibroblast growth factor receptor 2b), anti-TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domain), or anti-LAG3 (lymphocyte activation gene 3), among many other cancer targets, is to be encouraged. This evidence concerns the gene TIGIT and cancer.